ZANIDATAMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 13:34:27 UTC 2023` Edited by `admin` on `Sat Dec 16 13:34:27 UTC 2023`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	Z20OC92TDI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZANIDATAMAB

Official Name

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP

Common Name

English

ZW-25

Code

English

Zanidatamab [WHO-DD]

Common Name

English

ANTI-HER2 BI-SPECIFIC MONOCLONAL ANTIBODY ZW25

Common Name

English

ZANIDATAMAB [USAN]

Common Name

English

zanidatamab [INN]

Common Name

English

IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 LIGHT CHAIN VARIABLE REGION FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 20-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN-MUS MUSCULUS BIPARA

Common Name

English

ZW25

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C155711

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

NCI_THESAURUS

C28227

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

FDA ORPHAN DRUG

715119

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

FDA ORPHAN DRUG

554716

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

FDA ORPHAN DRUG

519516

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

Code System Code Type Description

USAN

HI-248

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

FDA UNII

Z20OC92TDI

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

DRUG BANK

DB15471

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

NCI_THESAURUS

C130010

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

INN

10997

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

CAS

2169946-15-8

Created by admin on Sat Dec 16 13:34:27 UTC 2023 , Edited by admin on Sat Dec 16 13:34:27 UTC 2023

PRIMARY

From	To
1_24	1_89
1_150	1_224
1_261	2_229
1_264	2_232
1_296	1_356
1_402	1_460
2_23	2_97
2_147	2_203
2_223	3_215
2_264	2_324
2_370	2_428
3_24	3_89
3_135	3_195

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_332
N	2_300

Related Record Type Details


					HKH2GV9PVO

ZANIDATAMAB ZOVODOTIN

CONJUGATE -> PARENT

Amount:


					7J9Y28299R

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2

TARGET -> INHIBITOR

Interaction Type:

BINDING

Related Record Type Details


					Z20OC92TDI

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL